The big comeback for growth and a major setback for travel The big comeback for growth and a major setback for travel The big comeback for growth and a major setback for travel

The big comeback for growth and a major setback for travel

Equities 5 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  Our NextGen Medicine and Bubble Stocks theme baskets are the big winners in June as inflation expectations have fallen as more market participants are buying into the Fed narrative of transitory inflation and a more hawkish FOMC. We also take a quick look at Appian which is the best-performing stock within the Bubble Stocks basket. Finally, we are covering the recent declines in travel stocks due to the new emerging Covid-19 Delta variant that could negatively impact this year's summer holiday in Europe.

June manifested itself as the big comeback month for growth stocks with theme baskets such as NextGen Medicine (up 17.6% in June) and Bubble Stocks (up 10.3% in June) powering ahead fueled by a more hawkish FOMC causing long-term US interest rates and inflation expectations to decline. The NextGen Medicine basket got an additional boost from the major gene editing breakthrough by Intellia Therapeutics which we covered in yesterday’s equity update.

Bubble stocks started their rebound back in mid-May and have since risen 21% likely causing a sigh of relief for Ark Invest and in general growth investors. While growth has staged a comeback and we believe investors should have these growth pockets in their portfolios, we are also still leaning towards inflation will run higher than current market consensus causing interest rates to climb higher over the coming year reducing the tailwind for growth stocks. Below the performance chart on our Bubble Stocks basket we have inserted the companies in the basket and if we look across performance last month the best-performing stock has been Appian.

Appian sells a low-code automation platform and solutions that maximizes resource use for businesses but has been under pressure since the peak back in February. In June, the stock finally rallied without any particular news until 17 June when the stock was added to Hedgeye’s new best idea long based on the views that Appian is doing the right things on pricing, community development and partner integration.

NameDomicileMkt Cap (USD mn.)12M Fwd EPS12M Fwd EV/SalesDiff to PT (%)5yr return (%)
Kuaishou TechnologyChina213,499-0.8516.260.3NA
Sea LtdSingapore140,384-1.2617.312.3NA
Airbnb IncUnited States130,635-1.3128.18.7NA
NIO IncChina94,795-1.5918.011.8NA
Snowflake IncUnited States84,570-0.8771.520.1NA
DoorDash IncUnited States67,743-0.1917.6-6.5NA
Roku IncUnited States59,111-0.2623.13.7NA
Bilibili IncChina51,601-4.7618.218.8NA
Teladoc Health IncUnited States41,124-0.3020.337.9928.6
XPeng IncChina37,228-2.4115.03.2NA
Affirm Holdings IncUnited States34,499-0.8939.714.3NA
BeiGene LtdChina34,490-9.7835.812.41,071.9
Unity Software IncUnited States34,299-0.3532.714.6NA
Plug Power IncUnited States32,156-0.1868.134.91,702.4
Seagen IncUnited States31,016-0.1115.916.3280.4
Cloudflare IncUnited States28,050-0.0846.1-5.6NA
Splunk IncUnited States27,486-0.2110.813.3166.0
MongoDB IncUnited States25,201-0.9834.11.4NA
Exact Sciences CorpUnited States24,752-1.1413.322.1915.2
Gaotu Techedu IncChina24,455-3.3411.8NANA
Farfetch LtdUnited Kingdom23,465-0.6610.321.2NA
DraftKings IncUnited States23,186-1.1626.531.9NA
GDS Holdings LtdChina20,998-0.1518.634.2NA
10X Genomics IncUnited States20,458-0.3238.97.7NA
Argenx SENetherlands19,397-10.72105.25.32,055.5
Alnylam Pharmaceuticals IncUnited States19,214-4.7721.02.8172.2
Ping An Healthcare and Technology Co LtdChina18,942-0.9111.627.8NA
Innovent Biologics IncChina18,305-0.6124.016.6NA
Guardant Health IncUnited States16,826-1.5040.532.0NA
Zai Lab LtdChina15,781-2.5287.58.4NA
Kingsoft Cloud Holdings LtdChina15,710-2.569.656.9NA
Yatsen Holding LtdChina15,665-1.1710.740.2NA
Oak Street Health IncUnited States15,461-0.4611.123.3NA IncUnited States15,370-0.7969.657.7NA Holdings IncUnited States15,319-0.1957.4-2.5NA
Canopy Growth CorpCanada15,279-0.9024.213.9990.2
Appian CorpUnited States15,229-0.4043.3-22.4NA
Avalara IncUnited States14,770-0.1621.314.3NA
Elastic NVUnited States14,429-0.4420.616.0NA
Cree IncUnited States14,240-0.5921.317.5296.1
Aggregate / median1,565,14121.314.6857.9

Source: Bloomberg and Saxo Group

Source: Bloomberg

Delta variant is a key risk for travel stocks

The emerging Covid-19 variant called ‘Delta’ is coming a key risk for European tourism which is not only a blow to Southern Europe that is in desperate need of a rebound in their tourist income, but also travel stocks that are down 6.2% in June. While investors have reacted to the uncertainty selling off travel stocks, the recent data from the UK and Israel suggest that while new cases are increasing due to the new Delta variant the number of hospitalizations and severe cases of Covid-19 are not dramatically increasing suggesting that vaccinations are working. The recent selloff in travel stocks is healthy as the rebound in travel stocks has been too much relative to what we can expect of profitability and growth from the industry in the coming years.

Source: Bloomberg

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (
- Analysis Disclaimer (
- Notification on Non-Independent Investment Research (

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.